clinical trial · NCT06144944
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·phase3·active not recruiting·n = 160
Breast Cancer InvasiveHormone-receptor-positive Breast CancerHER2 Low Breast CarcinomaEarly-stage Breast CancerPyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxelEpirubicin or doxorubicin, cyclophosphamide, paclitaxel
brief summary
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative) high-risk early breast cancer
started
Jan 17, 2024
primary completion
Jul 18, 2026
completion
Dec 31, 2031
last updated
Aug 18, 2026
official title
Neoadjuvant Pyrotinib Combined With Chemotherapy Versus Chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative) High-risk Early Breast Cancer: an Open-lable, Multi-center, Randomized Phase III Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol